echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Study finds inhibition of PDK1 holds promise for acute myeloid leukemia

    Study finds inhibition of PDK1 holds promise for acute myeloid leukemia

    • Last Update: 2022-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Acute myeloid leukemia (AML) remains difficult to treat because of high genetic heterogeneity not only between different patients, but also between subclonal populations of cancer cells within the same patient


    Now, in a new study, researchers from research institutions such as the University of Groningen in the Netherlands and the University of Barcelona in Spain have found that a key enzyme in glucose metabolism, pyruvate dehydrogenase kinase 1 (PDK1), is a key enzyme in leukemia stem cells containing a large number of leukemia stem cells.


    PDK1: a determinant of different metabolic states

    PDK1: a determinant of different metabolic states

    In the new study, PDK1 was identified as a determinant of different metabolic states


    Integrated metabolomic, proteomic and transcriptomic analysis of major energy flows in AML and normal hematopoietic stem/progenitor cells

    Image via Nature Communications, 2022, doi:10.


    The authors applied metabolomic, proteomic, genomic and transcriptomic techniques, as well as gene ontology and gene set enrichment analysis (GSEA), among others


    These findings also indicate that inhibition of PDK1 induces mitochondrial stress and improves the efficacy of glutaminase inhibitor-based antitumor therapies


    Note: The original text has been deleted

    References:

    Ayşegül Erdem et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.